Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576702 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
A Phase 2 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 2
- Development phase
- 471
- Enrollment target
NCT04576702 is a Phase 2 study that has completed, run by Seqirus. The registered enrollment target is 471 participants.
The verdict
NCT04576702, a Phase 2 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 471 participants
- Enrollment target
Study Summary
This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 480 subjects are to be randomized into 1 of 4 possible treatment groups (investigational Influenza Vaccine or licensed Quadrivalent Influenza Vaccine comparators) at 120 participants per group. Every participant will receive an influenza vaccine injection on Day 1 and will be followed up for approximately 6 months following injection. The primary immunogenicity analysis is based on Day 29 serum.
Interventions
- BIOLOGICAL Investigational aIIV4c
- BIOLOGICAL IIV4c
- BIOLOGICAL aIIV4
- BIOLOGICAL RIV4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2021-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04576702
The ClinicalTrials.gov registry entry for NCT04576702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Investigational aIIV4c is the first listed.
NCT04576702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04576702 about?
NCT04576702 is a clinical study titled "Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults". This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 480 subjects are to be randomized into 1 of 4 possible treatment groups (inv...
What is the current status of trial NCT04576702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 471 participants. The study started on 2020-10-08. Estimated completion is 2021-05-24.
What interventions are being tested in trial NCT04576702?
The interventions under investigation include: Investigational aIIV4c (BIOLOGICAL), IIV4c (BIOLOGICAL), aIIV4 (BIOLOGICAL), RIV4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04576702?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.